| |
Study 1 |
Study 2 |
Study 3 |
Study 4 |
Study 5 |
Study 6 |
| Characteristic |
(N=64) |
(N=74) |
(N=64) |
(N=64) |
(N=64) |
(N=83) |
| Age (years) |
|
|
|
|
|
|
| Mean (SD) |
34.7 (11.8) |
32.9 (10.9) |
36.6 (8.4) |
36.0 (10.4) |
37.8 (8.1) |
34.2 (11.4) |
| Range |
(19;54) |
(19;55) |
(19;54) |
(18;54) |
(21;55) |
(20;55) |
| Sex, n (%) |
|
|
|
|
|
|
| Female |
27 (42) |
31 (42) |
22 ( 34) |
27 ( 42) |
28 ( 44) |
44 (53) |
| Male |
37 (58) |
43 (58) |
42 ( 66) |
37 ( 58) |
36 ( 56) |
39 (47) |
| Race, n (%) |
|
|
|
|
|
|
| White |
59 (92) |
59 (80) |
61 (95) |
61 (95) |
62 ( 97) |
70 (84) |
| Black or African American |
4 (6) |
10 (14) |
3 (5) |
2 (3) |
1 (2) |
11 (13) |
| Other |
1 (2) |
5 (7) |
0 |
1 (2) |
1 (2) |
2 (2) |
| Weight (kg) |
|
|
|
|
|
|
| Mean (SD) |
75.3 (12.7) |
75.2 (11.6) |
73.1 (11.2) |
72.7 (11.5) |
72.6 (11.2) |
75.4 (11.7) |
| Range |
(54;106) |
(54;103) |
(52;106) |
(50;95) |
(52;97) |
(54;104) |
| Height (cm) |
|
|
|
|
|
|
| Mean (SD) |
172.4 (9.6) |
172.1 (9.8) |
167.9 (10.1) |
167.4 (9.8) |
166.4 (8.7) |
171.5 (9.0) |
| Range |
(153;190) |
(152;196) |
(149;192) |
(151;191) |
(151;184) |
(148;191) |
| BMI (kg/m2) |
|
|
|
|
|
|
| Mean (SD) |
25.2 (2.5) |
25.3 (2.7) |
25.9 (2.7) |
25.8 (2.4) |
26.1 (2.8) |
25.5 (2.5) |
| Range |
(21;30) |
(19;30) |
(20;30) |
(21;30) |
(20;30) |
(20;30) |
Note: In each study, participants received 2 canagliflozin/metformin IR FDC tablets or equivalent doses of canagliflozin and metformin as individual component IR tablets.
BMI = body mass index; N = total sample size; n = size of subsample; SD = standard deviation; IR = immediate release; FDC = fixed-dose combination. |
